Because the increase in IL-17A and IL-22 was not observed during the induction phase of colitis (Figure S1e), we opted to administer neutralizing antibodies into mice during the recovery phase on days 9, 11, and 13 (Figure 3a). The gene discussed is IL17A; the disease is colitis.